IBRX vs RF
Immunitybio Inc (IBRX) versus RF (RF) — a side-by-side from cached financials, not a winner call.
Immunitybio Inc (IBRX) is a biotechnology company listed on US.
RF (RF) common stock.
Latest reported IBRX revenue for 2025-12-31 was $113.3M. Net income was -$351.4M. Revenue was up 668.3% from 2024-12-31 to 2025-12-31. IBRX currently screens at market cap $7.88B.
RF does not have a complete income-statement cache yet.
IBRX currently screens at market cap $7.88B. RF currently screens at market cap $0.
Not investment advice. Open the IBRX and RF stock pages for the full models.
Not investment advice.